ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

July 9-13, 2022. London, England, UK.

View by Title View by Number View Themes
  • Abstract Number: LB 01.1

    A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

    G. Kenet1, B. Nolan2, B. Zulfikar3, B. Antmen4, P. Kampmann5, T. Matsushita6, C. You7, K. Vilchevska8, C. Bagot9, A. Sharif10, F. Peyvandi11, G. Young12, C. Negrier13, T. Quan14, S. Poloskey15, C. Sussebach16, F. Shammas17, S. Andersson18, B. Mei18, K. Kavakli19

  • Abstract Number: LB 01.2

    Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial

    V. Jiménez Yuste1, P. Angchaisuksiri2, G. Castaman3, K. Cepo4, J. Haaning4, S. Jacobsen4, J. Mahlangu5, T. Matsushita6, K. Nogami7, A. Shapiro8

  • Abstract Number: LB 01.3

    Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

    J. Mahlangu1, H. Chambost2, S. Chou3, A. Dunn4, A. von Drygalski5, R. Kaczmarek6, G. Kenet7, M. Laffan8, A. Leavitt9, B. Madan10, J. Mason11, J. Oldenburg12, M. Ozelo13, F. Peyvandi14, D. Quon15, M. Reding16, S. Shapiro17, H. Yu18, T. Robinson18, S. Pipe19

  • Abstract Number: LB 01.4

    Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

    A. von Drygalski1, P. Chowdary2, R. Kulkarni3, S. Susen4, B. Konkle5, J. Oldenburg6, D. Matino7, R. Klamroth8, A. Weyand9, V. Jimenez Yuste10, K. Nogami11, S. Poloskey12, B. Winding13, A. Willemze14, K. Knobe15

  • Abstract Number: LB 01.5

    Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis

    H. Vu1, T. Kohs1, J. Pang1, K. Jordan1, T. Zheng1, P. Kievit2, J. Johnson1, M. Wallisch3, M. Hinds1, C. Puy1, C. Lorentz3, E. Tucker4, D. Gailani5, J. Aslan1, J. Shatzel1, O. McCarty6, I. Parra-Izquierdo1

  • Abstract Number: LB 02.1

    Intermediate versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow Study)

    I. Bistervels1, A. Buchmuller2, H. Wiegers3, F. Ní Áinle4, B. Tardy5, J. Donnelly6, P. Verhamme7, A. Jacobsen8, A. Hansen9, M. Rodger10, M. DeSancho11, R. Shmakov12, N. van Es3, M. Prins13, C. Chauleur14, S. Middeldorp15

  • Abstract Number: LB 02.2

    Hemorrhagic, Coagulopathic, and Thrombotic (HECTOR) Complications Among Critically-Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study

    J. Fanning1, R. Fanning2, N. Weaver3, M. Griffee4, S. Cho1, M. Panigada5, A. Zaaqoq6, N. White7, N. Obonyo8, A. Labib9, Y. Chia10, B. Fan11, R. Arora12, D. Chiumello13, A. Torres14, J. Suen15, G. Li Bassi15, G. Peek16, J. Fraser15, H. Dalton17

  • Abstract Number: LB 02.3

    Sirtuin 1 as an endogenous inhibitor of NETosis

    L. Wang1, C. Yuen1, S. Wong2

  • Abstract Number: LB 02.4

    Platelets as Versatile Effectors of Thromboinflammation in Chronic Myeloproliferative Neoplasms

    A. Krishnan1, Z. Shen2

  • Abstract Number: LB 02.5

    Roles of FVIII in endothelial cell biology more than a coagulation factor

    c. olgasi1, A. Cucci2, S. Assanelli2, C. Sgromo2, C. Borsotti2, G. Walker2, I. Molineris3, F. Anselmi3, S. Oliviero3, A. Follenzi4

  • Abstract Number: OC 01.1

    Base and Prime editing of DNA as a new therapeutic option for Hemophilia A

    E. Tonetto1, S. Pignani2, G. Roman2, A. Follenzi2, F. Bernardi3, D. Liu4, M. Pinotti1, D. Balestra1

  • Abstract Number: OC 01.2

    Improvements in Health-Related Quality of Life in Adults with Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

    R. Itzler1, J. Miller2, R. Robson2, P. Monahan3, S. Pipe4

  • Abstract Number: OC 01.3

    Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

    A. Sternberg, B. Samelson-Jones, L. George

  • Abstract Number: OC 01.5

    Innate and Adaptive Immune Responses to Adeno-Associated Viral Gene Therapy in the Severe Hemophilia A Dog Model

    P. Batty1, A. Mo2, M. Ashrafali3, B. Yates3, A. Gonzalez3, B. Handyside3, L. Harpell2, D. Hurlbut2, A. Menard4, A. Pender2, L. Razon3, C. Sihn3, A. Winterborn2, S. Fong3, D. Lillicrap5

  • Abstract Number: OC 02.1

    Complement Receptors Mediate Binding of Heparin-Induced Thrombocytopenia Immune Complexes to Fc Receptor Bearing Cells

    H. Harris1, S. Khandelwal2, L. Rauova3, D. Cines4, G. Arepally2

  • Abstract Number: OC 02.2

    Cooperation between PF4-specific antibodies in heparin-induced thrombocytopenia: a new mechanism potentially contributing to hypercoagulability and thrombosis

    S. Billy1, C. Vayne2, N. Charuel3, L. Coënon3, M. Atsouawe3, C. Pouplard4, Y. Gruel2, J. Rollin2

  • Abstract Number: OC 02.3

    “Off-the-shelf” cryopreserved platelets for the detection of HIT and VITT antibodies

    A. Kanack1, C. Jones2, N. Splinter3, R. Leger3, N. Heikal3, D. Chen3, R. Pruthi3, G. George4, Y. Abou-Ismail5, G. Wool6, K. Gundabolu7, A. Padmanabhan3

  • Abstract Number: OC 02.4

    Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies

    A. Padmanabhan1, A. Kanack2, B. Singh1, G. George3, K. Gundabolu4, S. Koepsell4, Y. Abou-Ismail5, K. Moser5, K. Smock5, D. Green6, A. Major7, C. Chan7, G. Wool7, M. Reding8, A. Ashrani1, A. Bayas9, D. Grill1

  • Abstract Number: OC 02.5

    In vivo murine studies demonstrate that neutrophil activation by anti-NAP2 antibodies contributes to vaccine-induced immune thrombocytopenia and thrombosis (VITT)

    C. Field1, H. Kim2, M. Kowalska2, M. Weitzman2, G. Arepally3, D. Cines4, L. Rauova2, M. Poncz2

  • Abstract Number: OC 03.1

    Factor XII heavy chain structure

    J. EMSLEY1, M. saleem2, C. Li1, H. Philippou3

  • 1
  • 2
  • 3
  • …
  • 94
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley